Clinical Trials Browser

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT04628988 2023-09-13

A Study of CC-90011 and Comparators in Participants With Prostate Cancer

Phase 1 Completed

6 enrolled

Genitourinary

Prostatic Neoplasms

NCT03569280 2023-07-18

Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients

Phase 1 Completed

16 enrolled

Genitourinary

Prostatic Neoplasms

NCT04179396 2023-06-29

RAMP

Phase 1 Completed

8 enrolled 8 charts

Genitourinary

Metastatic Castration Resistant Prostate Cancer

NCT03150056 2022-08-10

Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy in Participants With Castrate-resistant Prostate Cancer

Phase 1 Terminated

73 enrolled 34 charts

Other solid neoplasm

Solid Tumours

NCT04087174 2022-07-13

A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer

Phase 1 Completed

27 enrolled

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT01574937 2021-08-06

XL-184+Abiraterone in Post-Chemo CRPC

Phase 1 Completed

27 enrolled

Genitourinary

Prostatic Neoplasms

NCT02883166 2020-12-07

SNACK

Phase 1 Completed

14 enrolled

Genitourinary

Prostatic Neoplasms

NCT01741753 2019-02-05

BKM120+Abiraterone Acetate for Metastatic CRPC

Phase 1 Terminated

4 enrolled

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT02380313 2016-10-06

Dose-Finding Study of Afuresertib Administered in Combination With Either Enzalutamide or Aibraterone

Phase 1 Withdrawn

Tumor-Agnostic

Neoplasms

Clinical Trials

SNV1521 in Participants With Advanced Solid Tumors

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)

Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer

Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose.

Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer

Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer

Trial of ARV-110 and Abiraterone in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

PK and Dose Escalation and Expansion Study of DST-2970

A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors

Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)

Study of PCUR-101 in Combination With ADT in Patients With mCRPC

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

A Study of CC-90011 and Comparators in Participants With Prostate Cancer

Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients

RAMP

Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy in Participants With Castrate-resistant Prostate Cancer

A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer

XL-184+Abiraterone in Post-Chemo CRPC

SNACK

BKM120+Abiraterone Acetate for Metastatic CRPC

Dose-Finding Study of Afuresertib Administered in Combination With Either Enzalutamide or Aibraterone